Abstract
This Commentary addresses the FDA approval of pembrolizumab and the changes necessary in clinical practice to identify patients who would benefit from such treatment.
MeSH terms
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Drug Approval / methods*
-
Humans
-
Neoplasms / drug therapy*
Substances
-
Antibodies, Monoclonal, Humanized
-
pembrolizumab